Trimetazidine Inhibits Neutrophil Accumulation After Myocardial Ischaemia and Reperfusion in Rabbits

Williams, Frances; Tanda, K.; Kus, M.; Td, Williams

doi:10.1097/00005344-199312000-00008

Cited by 78 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TMZ reduces intracellular accumulation of sodium and calcium and inhibits platelet ad- hesion-aggregation, neutrophil infiltration, and the generation or activity of oxygen-derived free radicals [l, 9, 221. The potent antioxidant effect of T M Z has been demonstrated in myocardial, renal, and hepatic IR injury [7,17,20,22]. A significant increase in MDA levels has been observed in various organs including the liver, kidney, and intestine during IR injury [7,16,19,23,24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats

Tetik¹,

Özden²,

Çallı³

et al. 1999

Transplant Int

View full text Add to dashboard Cite

Trimetazidine (TMZ), a potent antioxidant agent, has been used to protect the myocardium, liver and kidney from ischemia reperfusion (IR) injury. We investigated the effect of TMZ, a cellular antiischemic agent and a free radical scavenger, on 60 rnin of warm intestinal IR injury in rats. SpragueDawley rats were divided into three groups: a sham-operated group (no IR injury, n = S), an ischemic control group (control, n = 8), and a TMZtreated group (3 mg/kg, y1 = 8). Malondialdehyde (MDA) levels, myeloperoxidase (MPO) activity, and mucosal damage were investigated after 120 min of reperfusion. MDA levels and MPO activity were more elevated and histopathological damage more severe in the control group than in the sham group ( P < 0.05). MDA levels and MPO activity were lower and there was less histopathological damage in the T M Z group than in the control group ( P < 0.0s). Accumulation of lipid peroxidation products and neutrophils in mucosal tissues were significantly inhibited by TMZ treatment. We conclude that pretreatment of rats with TMZ before intestinal ischemia attenuates but does not prevent, histological damage.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Trimetazidine (TMZ), a potent antioxidant agent, has been used to protect IR injury of the myocardium, liver, and kidney [7,17,20,22]. However, there is no report on the use of T M Z in intestinal IR injury.…”

Section: Introductionmentioning

confidence: 99%

Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats

Tetik¹,

Özden²,

Çallı³

et al. 1999

Transplant Int

View full text Add to dashboard Cite

show abstract

“…Experimentally, it reduces infarct size, decreases platelet aggregation and limits leucocyte influx into the infarct zone (Belcher et al 1993;Williams et al 1993;Noble et al 1995). In double-blind placebocontrolled trials, trimetazidine significantly improved symptom-limited exercise performance in stable angina patients when used either as monotherapy or in combination with traditional cardiovascular drugs such as nitrates, β -blockers or Ca ++ channel antagonists (Levy 1995;Manchanda and Krishnaswami 1997;Szwed et al 2001a).…”

confidence: 99%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Percutaneous transluminal coronary angioplasty (PTCA) has been recognized as a reliable treatment procedure for acute reversible ischemia and reperfusion. Ischemic reperfusion cycle in PTCA leads to the systemic inflammation and extensive tissue injury by the production of reactive oxygen species including nitric oxide (NO) radicals. In patients with coronary artery disease, undergoing PTCA, the effects of trimetazidine (TMZ), a piperazine-derivative anti-anginal drug, were studied on several indirect markers of systemic inflammatory response: tumor necrosis factor-α (TNF-α ), C-reactive protein (CRP) and NO products (nitrite and nitrate). Patients (n = 11 each group) were untreated or pre-treated with TMZ (20 mg per orally three times a day), begun three days prior to PTCA, and marker levels were measured before the start of TMZ therapy (baseline), just before PTCA (0 hr), and 4, 24, and 48 hrs after PTCA. The baseline levels of markers were not significantly different between the untreated and pre-treated patients. In contrast, all parameters were lower in the TMZtreated group than those in the matched control group in the pre-and post-angioplasty periods. Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre-and post-angioplasty periods, but the TNF-α levels were significantly decreased only in the post-angioplasty period. Preprocedural treatment with oral TMZ for three days significantly suppressed the elevation of inflammatory markers before and shortly after PTCA. We suggest the usefulness of TMZ in preventing inflammatory cardiovascular events after PTCA.trimetazidine; percutaneous transluminal coronary angioplasty; C-reactive protein; nitric oxide; tumor necrosis factor-α .

show abstract

“…The anti-inflammatory effect of trimetazidine can be attributed to decrease the levels of TNF α , NO products and CRP. [7][8][9][10] Though the results of the present study do not point at actual mechanism of trimetazidine on inflammation, this effect can be attributed to the effect of trimetazidine to decrease TNF α as reported in previous studies. [7][8][9][10] This study shows that in addition to anti anginal activity, trimetazidine may also possess anti-inflammatory properties that could be of additional benefit in the treatment of atherosclerosis and their complications like reinfarction and infarct extension, and also in preventing cardiovascular events like restenosis after PCI.…”

Section: Discussionmentioning

confidence: 56%

“…Interestingly certain studies have reported that metabolic modulator trimetazidine, which is an antianginal drug, inhibits the inflammatory markers like C reactive protein(CRP), nitric oxide products (nitrite and nitrates), interleukins (IL-1, IL-6) and TNF alpha. [7][8][9] But another study suggested that trimetazidine showed no significant reduction in the levels of IL-8, TNF-α, complement 3 and 5 and CRP. 10 Review of literature revealed paucity of studies regarding anti-inflammatory activity of the above mentioned drug in animals.…”

Section: Introductionmentioning

confidence: 99%

Effect of trimetazidine on acute and sub-acute models of inflammation in male wistar rats

Naveena

Hashilkar

Davangeri

et al. 2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Trimetazidine Inhibits Neutrophil Accumulation After Myocardial Ischaemia and Reperfusion in Rabbits

Cited by 78 publications

References 0 publications

Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats

Cytoprotective effect of trimetazidine on 60 minutes of intestinal ischemia-reperfusion injury in rats

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Effect of trimetazidine on acute and sub-acute models of inflammation in male wistar rats

Contact Info

Product

Resources

About